
The patient was 52 years old and underwent a liver transplant 13 years after his hematopoietic stem cell transplant (HSCT) to treat his sickle cell disease (SCD).
Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.
He has an MA from University of Sioux Falls. You can connect with Jared on LinkedIn.

The patient was 52 years old and underwent a liver transplant 13 years after his hematopoietic stem cell transplant (HSCT) to treat his sickle cell disease (SCD).

The tool relies on factors including creatinine, anti–double-stranded DNA antibody, and gender, among others.

Just 5% of patients in a cholangiocarcinoma cohort were categorized as microsatellite instability high (MSI-high), but those patients tended to have “excellent” responses to therapy.

Patients who received a diagnosis of small cell lung cancer (SCLC) between 2010 and 2016 had a nearly 2% increase in overall survival vs those who received their diagnosis between 2004 and 2010.

Most patients taking a biologic stayed on the therapy, and most saw decreases in exacerbations, a new study has found.

Research supports markers like C-peptide not only for the diagnosis of type 1 diabetes (T1D), but also for patient management.

The data suggest the noninvasive procedure was successful in guiding food reintroduction, but missed some food triggers in certain patients.

A new report offers novel insights into a very small patient population.

About 43% of patients experienced complete depletion of B cells after the first round of rituximab, and those patients had greater odds of longer-term success.

A patient’s quick response to cemiplimab (Libtayo) was reversed after the therapy was stopped due to progression of apparent metastatic cutaneous squamous cell carcinoma.

A dichotomous classification scheme has helped in the intrahepatic cholangiocarcinoma (iCCA) space, but some potential variants require further exploration, the article states.

Levels of the hormone increase with disease severity, a new study has found.

The study, based on a case series in Japan, found the risk of grade 2 or above chemoradiation increased when durvalumab was started within 14 days of the final thoracic radiotherapy treatment.

Investigators said the benefits appeared relatively early in treatment for many patients and persisted throughout the study period.

A single-center analysis of more than 30 years of data shows rates of preterm births and preeclampsia remained stable

The study suggests standardized uptake values may be a useful marker to predict treatment response and prognosis in lung adenocarcinoma.

The investigators cautioned, however, that the factors identified had only modest predictive power.

Physicians should consider measuring anti-endothelial cell antibodies in patients with polycythemia vera, the investigators suggested.

A systematic review and meta-analysis found no clear advantage for automated red cell exchange.

Study data are mixed, but some evidence suggests the administration of vitamin D may work as a low-risk prophylactic against graft-versus-host disease (GVHD).

Hepatobiliary-phase enhanced imaging outperformed diffusion-weighted imaging in distinguishing intrahepatic mass-forming cholangiocarcinoma, but the accuracy is greater when these methods are used in tandem.

A new model may be able to better identify which patients will respond to immunotherapy.

The study, based on 33 years of data, also explored auto-antibody production in the rare patient group.

Levels of the 2 markers appeared to indicate both the presence of SLE and disease activity levels.

Patients said they benefited from diabetes management technology, but also from social accountability.

Investigators also found patients in nursing homes tend to have larger tumors and may experience quality-of-life benefits from the procedure.

Prior to the pandemic, youth with sickle cell disease were more likely to report depressive symptoms, but the opposite was true during the pandemic.

A cure for sickle cell disease could more than double the lifetime incomes of patients, the study found.

Forty-two percent of patients in the cohort had an adverse pregnancy outcome.

The analysis suggests the marker could be used to screen patients for potential immunotherapy.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
